Literature DB >> 21947761

Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Alicia Fernandez-Fernandez1, Romila Manchanda, Anthony J McGoron.   

Abstract

Successful cancer management depends on accurate diagnostics along with specific treatment protocols. Current diagnostic techniques need to be improved to provide earlier detection capabilities, and traditional chemotherapy approaches to cancer treatment are limited by lack of specificity and systemic toxicity. This review highlights advances in nanotechnology that have allowed the development of multifunctional platforms for cancer detection, therapy, and monitoring. Nanomaterials can be used as MRI, optical imaging, and photoacoustic imaging contrast agents. When used as drug carriers, nanoformulations can increase tumor exposure to therapeutic agents and result in improved treatment effects by prolonging circulation times, protecting entrapped drugs from degradation, and enhancing tumor uptake through the enhanced permeability and retention effect as well as receptor-mediated endocytosis. Multiple therapeutic agents such as chemotherapy, antiangiogenic, or gene therapy agents can be simultaneously delivered by nanocarriers to tumor sites to enhance the effectiveness of therapy. Additionally, imaging and therapy agents can be co-delivered to provide seamless integration of diagnostics, therapy, and follow-up, and different therapeutic modalities such as chemotherapy and hyperthermia can be co-administered to take advantage of synergistic effects. Liposomes, metallic nanoparticles, polymeric nanoparticles, dendrimers, carbon nanotubes, and quantum dots are examples of nanoformulations that can be used as multifunctional platforms for cancer theranostics. Nanomedicine approaches in cancer have great potential for clinically translatable advances that can positively impact the overall diagnostic and therapeutic process and result in enhanced quality of life for cancer patients. However, a concerted scientific effort is still necessary to fully explore long-term risks, effects, and precautions for safe human use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947761      PMCID: PMC3239222          DOI: 10.1007/s12010-011-9383-z

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  179 in total

Review 1.  Liposomes as drug carriers: a technological approach.

Authors:  M Brandl
Journal:  Biotechnol Annu Rev       Date:  2001

2.  Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer.

Authors:  Jaemoon Yang; Choong-Hwan Lee; Hyun-Ju Ko; Jin-Suck Suh; Ho-Geun Yoon; Kwangyeol Lee; Yong-Min Huh; Seungjoo Haam
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

3.  Quantum dot bioconjugates for ultrasensitive nonisotopic detection.

Authors:  W C Chan; S Nie
Journal:  Science       Date:  1998-09-25       Impact factor: 47.728

4.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo.

Authors:  A Mori; A L Klibanov; V P Torchilin; L Huang
Journal:  FEBS Lett       Date:  1991-06-24       Impact factor: 4.124

5.  A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.

Authors:  Stuart Emanuel; Robert H Gruninger; Angel Fuentes-Pesquera; Peter J Connolly; Jennifer A Seamon; Susan Hazel; Rose Tominovich; Beth Hollister; Cheryl Napier; Michael R D'Andrea; Michael Reuman; Gilles Bignan; Robert Tuman; Dana Johnson; David Moffatt; Mark Batchelor; Anne Foley; James O'Connell; Rodger Allen; Martin Perry; Linda Jolliffe; Steven A Middleton
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

Review 6.  Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

Authors:  James E Frampton; Gillian M Keating
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

7.  Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy.

Authors:  Zhonggao Gao; Anne M Kennedy; Douglas A Christensen; Natalya Y Rapoport
Journal:  Ultrasonics       Date:  2007-11-19       Impact factor: 2.890

8.  Release behaviour of 5-fluorouracil from chitosan-gel microspheres immobilizing 5-fluorouracil derivative coated with polysaccharides and their cell specific recognition.

Authors:  Y Ohya; T Takei; H Kobayashi; T Ouchi
Journal:  J Microencapsul       Date:  1993 Jan-Mar       Impact factor: 3.142

Review 9.  Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?

Authors:  A A Shvedova; E R Kisin; D Porter; P Schulte; V E Kagan; B Fadeel; V Castranova
Journal:  Pharmacol Ther       Date:  2008-12-06       Impact factor: 12.310

10.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

View more
  68 in total

1.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

2.  Hybrid anisotropic nanostructures for dual-modal cancer imaging and image-guided chemo-thermo therapies.

Authors:  Ruiping Zhang; Kai Cheng; Alexander L Antaris; Xiaowei Ma; Min Yang; Sindhuja Ramakrishnan; Guifeng Liu; Alex Lu; Hongjie Dai; Mei Tian; Zhen Cheng
Journal:  Biomaterials       Date:  2016-07-02       Impact factor: 12.479

3.  Multifunctional nanomedicines: potentials and prospects.

Authors:  Udita Agrawal; Madhu Gupta; Rajesh S Jadon; Rajeev Sharma; S P Vyas
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 4.  "Extremely minimally invasive": recent advances in nanotechnology research and future applications in neurosurgery.

Authors:  Tobias A Mattei; Azeem A Rehman
Journal:  Neurosurg Rev       Date:  2014-08-31       Impact factor: 3.042

Review 5.  Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Authors:  Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

7.  Hybrid magneto-plasmonic liposomes for multimodal image-guided and brain-targeted HIV treatment.

Authors:  Asahi Tomitaka; Hamed Arami; Zaohua Huang; Andrea Raymond; Elizette Rodriguez; Yong Cai; Marcelo Febo; Yasushi Takemura; Madhavan Nair
Journal:  Nanoscale       Date:  2017-12-21       Impact factor: 7.790

8.  Green synthesis of bimetallic Au@Pt nanostructures and their application for proliferation inhibition and apoptosis induction in human cervical cancer cell.

Authors:  Ali A Alshatwi; Jegan Athinarayanan; Vaiyapuri Subbarayan Periasamy
Journal:  J Mater Sci Mater Med       Date:  2015-03-13       Impact factor: 3.896

Review 9.  Coaxial electrospray of microparticles and nanoparticles for biomedical applications.

Authors:  Leilei Zhang; Jiwei Huang; Ting Si; Ronald X Xu
Journal:  Expert Rev Med Devices       Date:  2012-11       Impact factor: 3.166

10.  PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin A delivery.

Authors:  Naghmeh Hadidi; Farzad Kobarfard; Nastaran Nafissi-Varcheh; Reza Aboofazeli
Journal:  AAPS PharmSciTech       Date:  2013-03-12       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.